ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Mouse Models, Other"

  • Abstract Number: 2462 • ACR Convergence 2024

    A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis

    Enming Su1, Pei-Suen Tsou1, Mark Warnock2, Natalya Subbotina1, Kris Mann1, Sirapa Vichaikul1, Xianying Xing1, Enze Xing1, Olesya Plazyo1, Rachael Wasikowski1, Lam C. Tsoi3, Mark Weinberg4, Cory D. Emal5, Dinesh Khanna1, John Varga1, Thomas H. Sisson1, Johann Gudjonsson1 and Daniel Lawrence2, 1University of Michigan, Ann Arbor, MI, 2Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI, 4MDI, Ann Arbor, MI, 5EMU, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is a complex and heterogeneous condition characterized by progressive fibrosis in multiple organs. Currently, there is no known cure for SSc,…
  • Abstract Number: 2192 • ACR Convergence 2023

    New Inducible Mouse Model of Sjögren’s Syndrome Represents a Valuable Tool to Assess the Impact of Gene Knockout on the Disease’s Physiopathology

    Dorian Parisis1, Nargis Bolaky2, Anissa Benchehida2, Christoph Küper3, jason Perret2, Muhammad Soyfoo1 and Christine Delporte2, 1Hôpital Universitaire de Bruxelles - Hôpital Erasme, Brussels, Belgium, 2Faculté de médecine - Université Libre de Bruxelles, Brussels, Belgium, 3Institute for Molecular Medicine, MSH Medical School Hamburg, Hamburg, Germany

    Background/Purpose: Primary Sjögren's syndrome (pSS) is a chronic rheumatic disease characterized by lymphocytic infiltration of exocrine glands, resulting in sicca syndrome with extra-glandular autoimmune features.…
  • Abstract Number: 0008 • ACR Convergence 2023

    Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice

    Biji T Kurien1, Devavrat Dave1, Martha Tsaliki1, Valerie Lewis1 and R Hal Scofield2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK

    Background/Purpose: Sjögren's Disease is an autoimmune condition in which patients exhibit decreased salivary/lacrimal gland function and express autoantibodies that target the 60k molecular weight Ro…
  • Abstract Number: 0110 • ACR Convergence 2023

    Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss

    Christine Rysenga, Srilakshmi Yalavarthi, Wenying Liang, Claire Hoy, Cyrus Sarosh, Richard Lieberman, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid antibodies (aPL) induce obstetric complications associated with placental insufficiency by promoting trophoblast dysfunction and inflammation at the maternal-fetal interface. Neutrophils have been found…
  • Abstract Number: 0727 • ACR Convergence 2023

    A Novel Active Pemphigus Vulgaris Mouse Model Induced by Immunization with TLR Ligand Adjuvanted Recombinant Desmoglein 3 Protein Vaccine

    Changxing Gao, Zijun Wang and Qianjin Lu, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China; Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China. 3. Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China

    Background/Purpose: Pemphigus vulgaris (PV) is an autoimmune bullous skin disease mediated by desmoglein-3 (Dsg3) specific auto-antibody present in skin and mucosae. The binding of pathogenic…
  • Abstract Number: 0803 • ACR Convergence 2023

    IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome

    Matthew Eremita1, Omar Geier2, Joyce Hui-Yuen1 and Matthew Taylor3, 1Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 2Sepsis Research Laboratory, Feinstein Institutes for Medical Research, Manhasset, NY, 3Division of Pediatric Critical Care, Cohen Children's Medical Center, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Gene expression pathway analyses have identified altered Toll-like receptor…
  • Abstract Number: 0870 • ACR Convergence 2023

    Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis

    Uxía nogueira Recalde1, Patricia Díaz rodríguez2, Francisco J. Blanco3, Eduardo Dominguez Medina4 and Beatriz Carames5, 1Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, 2Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Pharmacy School, Santiago de Compostela, Spain, 3Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 4Center for Research in Molecular Medicine and Chronic Diseases, Santiago de Compostela, Spain, 5Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain

    Background/Purpose: Disease-modifying therapeutic agents to prevent progression of Osteoarthritis (OA) are an urgent clinical need. Targeting senescence and autophagy in chondrocytes with small molecules is…
  • Abstract Number: 0880 • ACR Convergence 2023

    CD14 Inhibition as a Potential Therapeutic in Post Traumatic OA

    Kevin Burt1, Vu Nguyen1, Lance Murphy2, De'Broski Herbert1, Robert Mauck1 and Carla Scanzello3, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 3Translational Musculoskeletal Research Center, Corp. Michael J Crescenz VA Medical Center,4Division of Rheumatology, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Osteoarthritis (OA) is the most common joint disorder, and growing evidence has identified inflammation to be a major driver of disease progression. During disease,…
  • Abstract Number: 1591 • ACR Convergence 2023

    Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis

    Kelsey Collins1, Kristin Lenz2, Arin Oestreich2, Luke Springer2, Antonina Akk2, Huimin Yan2, Xiaobo Wu2, John Atkinson3, Christine Pham4 and Farshid Guilak4, 1University of California San Francisco, San Francisco, CA, 2Washington University in St. Louis, St. Louis, MO, 3Washington University School of Medicine, St. Louis, MO, 4Washington University, St. Louis, MO

    Background/Purpose: Osteoarthritis (OA) is the leading cause of musculoskeletal pain, which is a primary driver of care-seeking behavior. There is lack of mechanistic information detailing…
  • Abstract Number: 1730 • ACR Convergence 2023

    Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients

    Rachel AUDO1, Jérome Thireau2, Louis Rauzier3, Marie Barozet1, JACQUES MOREL4, Patrice Bideaux3, alain Lacampagne2 and Claire Daien5, 1CHU Montpellier, Montpellier, France, 2PhyMedExp INSERM U1046, Montpellier, France, 3PhyMedExp U1046, Montpellier, France, 4Protocole thérapeutique immuno-rhumatologie, Montpellier, France, 5University Hospital, Montpellier, France

    Background/Purpose: Rheumatoid arthritis (RA) is associated with a high risk of cardiovascular (CV) risks, including accelerated atherosclerosis, left ventricular hypertrophy and decreased heart rate variability…
  • Abstract Number: 1776 • ACR Convergence 2023

    Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression

    Shaghayegh Foroozan1 and Nigil Haroon2, 1University Health Network/University of Toronto, Toronto, ON, Canada, 2University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of…
  • Abstract Number: 1784 • ACR Convergence 2023

    Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model

    Raminderjit Kaur1, M. Elaine Husni2, Unnikrishnan Chandrasekharan3 and Roberta Brambilla4, 1Cleveland Clinic, Cleveland,, OH, 2Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, 3Cleveland Clinic, Cleveland, OH, 4University of Miami Miller School of Medicine, Miami,, FL

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive autoimmune condition that affects both the skin and joints. It is characterized by increased levels of the…
  • Abstract Number: 1786 • ACR Convergence 2023

    Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis

    Lu Bai1, Chengkai Zhu1, Yihong Xu2, Kunhai Tang1, Dachun Zhuo1, Qing Zhang1, Chengchun Geng1, Weidong Xu2, Hao Wu1, Xingdong Chen1 and Jiucun Wang1, 1Fudan University, Shanghai, China, 2Changhai Hospital, Shanghai, China

    Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease of the spinal joints leading to progressive loss of spinal mobility and chronic pain. Gutdysbiosis has been…
  • Abstract Number: 1788 • ACR Convergence 2023

    The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis

    Sungsin Jo1, Seung Hoon Lee1, Chanhyeok Jeon1, Sung Hoon Choi2, Ye-Soo Park3 and Tae-Hwan Kim4, 1Hanyang University Institute for Rheumatology Research, Seoul, South Korea, 2Hanyang University Seoul Hospital, Seoul, South Korea, 3Hanyang University College of Medicine, Guri, South Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Enthesitis is one of the most distinctive features and signs of ectopic bone formation in ankylosing spondylitis (AS). The Wnt/β-catenin pathway and Th17 cells…
  • Abstract Number: 1789 • ACR Convergence 2023

    Microtrauma Exacerbates Arthritis and Enthesitis in Curdlan-administered SKG Mice by Inducing FGF16 Expresssion

    Seung Hoon Lee1, Chanhyeok Jeon1, Sungsin Jo1 and Tae-Hwan Kim2, 1Hanyang University Institute for Rheumatology Research, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Microtrauma might be considered a crucial of various environmental factors in AS, but there is still unknown whether microtrauma has a direct/indirect role in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology